Your browser doesn't support javascript.
loading
NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.
Baggio, Carlo; Kulinich, Anna; Dennys, Cassandra N; Rodrigo, Rochelle; Meyer, Kathrin; Ethell, Iryna; Pellecchia, Maurizio.
Afiliação
  • Baggio C; Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
  • Kulinich A; Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
  • Dennys CN; Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.
  • Rodrigo R; Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.
  • Meyer K; Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.
  • Ethell I; Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
  • Pellecchia M; Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
J Med Chem ; 64(15): 11229-11246, 2021 08 12.
Article em En | MEDLINE | ID: mdl-34293864
ABSTRACT
In this paper, we applied an innovative nuclear magnetic resonance (NMR)-guided screening and ligand design approach, named focused high-throughput screening by NMR (fHTS by NMR), to derive potent, low-molecular-weight ligands capable of mimicking interactions elicited by ephrin ligands on the receptor tyrosine kinase EphA4. The agents bind with nanomolar affinity, trigger receptor activation in cellular assays with motor neurons, and provide remarkable motor neuron protection from amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Structural studies on the complex between EphA4 ligand-binding domain and a most active agent provide insights into the mechanism of the agents at a molecular level. Together with preliminary in vivo pharmacology studies, the data form a strong foundation for the translation of these agents for the treatment of ALS and potentially other human diseases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Receptor EphA4 / Fluorenos / Aminoácidos / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Receptor EphA4 / Fluorenos / Aminoácidos / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2021 Tipo de documento: Article